A Philadelphia trial judge overseeing mass tort litigation involving the digestive drug Reglan on Friday denied a bid by generic manufacturers to dismiss claims against them in roughly 2,000 lawsuits on the basis of a recent U.S. Supreme Court decision.
Philadelphia Common Pleas Court Judge Sandra Mazer Moss overruled without prejudice preliminary objections by generic companies that had argued that under the Supreme Court’s decision Pliva v. Mensing , state claims against them for failing to warn about the risks of taking the drug were pre-empted by federal regulations.
